New York-based Synergy Pharmaceuticals, developer of gastrointestinal disorder drugs, is talking to advisers about a potential sale of the company, according to Bloomberg sources.
Earlier this month, Salix -- which competes with Synergy in the gastrointestinal field -- was purchased by Valeant Pharmaceuticals for $10 billion.
Bloomberg sources say the sale of Synergy may depend on the results of a late-stage trial of IBS drug plecanatide, which should be announced in May.
Read the Bloomberg article
